At the beginning of 2018, pharmaceutical equipment companies began to announce their 2017 financial results. The author searched the financial reports released by five listed pharmaceutical equipment companies through relevant channels, including Chutian Technology, Kunshan Xinlai, Dongfulong, Canaan Technology, Qianshan Pharmaceutical Machinery, which can be described as mixed. New products and market demand boost Chutian Technology and Kunshan Xinlai's 2017 performance Let's take a look at the pharmaceutical equipment companies that report good results. Among the five companies that have released their 2017 financial results, Chutian Technology and Kunshan Xinlai have seen their performances rise last year. Among them, Chutian Technology's total revenue in 2017 reached 1,287,712,219.86 yuan, an increase of 32.32% over the same period of last year; operating profit of 125,777,790.08 yuan, an increase of 5. 18%; total profit was 134,139,902.69 yuan, an increase of 0.97% over the same period of the previous year. Kunshan Xinlai Group achieved operating income of 637,747,334.17 yuan in 2017, up 30.08% over the same period of last year; operating profit was 26,882,852.77, up 115.83% over the same period of last year; total profit 29, 339,278.21, up 135.71% over the same period last year. Kunshan Xinlai Group's performance report said that the company has benefited from the rapid development of the semiconductor industry, achieved good results in market development, and achieved rapid growth in revenue. In addition, the company has also optimized its internal management and made efforts to increase sales and management costs, thus achieving effective control over sales and management expenses. The rectification of Kunshan Unilig Pressure Vessel Co., Ltd., a wholly-owned subsidiary, and the improvement of customer repayment status are also factors that cannot be ignored in the company's performance. Dongfulong and Canaan's operating income increased, and the performance of Qianshan Pharmaceutical Machinery decreased. East Fulong and Canaan Technology's operating income increased in 2017, but operating profit and net profit attributable to shareholders of listed companies decreased compared with last year. In addition, the performance of Qianshan Pharmaceutical Machinery in 2017 also declined. Specifically, Dongfulong's annual total operating income was 1,705,899,900 yuan, up 28.48% over the same period of last year; operating profit was 171,300,300 yuan, down 34.56% from the same period of last year; The net profit of the shareholders of the listed company was RMB 13,427,600, a decrease of 42.74% compared with the same period of last year. According to the Canaan Science and Technology Financial Report, the total business revenue of the company in 2017 was 445.904 million yuan, an increase of 47.75% over the same period of the previous year; the total profit was 540.776 million yuan, a decrease of 22.50% over the same period of the previous year; The net profit of the shareholders of the listed company was 41.362 million yuan, a decrease of 27.49% over the same period of the previous year. During the reporting period, Qianshan Pharmaceuticals achieved operating income of 31,209,140 yuan, a decrease of 59.86% over the same period of the previous year; realized operating profit of -7,308.42 million yuan, a decrease of 2000.87% over the same period of the previous year; 283.6057 million yuan, down 234.83% over the same period of last year; net profit attributable to shareholders of listed companies was -24,229,600 yuan, down 227.21% over the same period of the previous year. For the reasons for the change in performance, Dongfulong Financial News reported that during the reporting period, the company was affected by the fierce competition in the pharmaceutical equipment industry, the overall decline in the gross profit margin of the industry and the significant increase in labor costs and expenses. Canaan Science and Technology Financial Report shows that during the reporting period, the company continued to improve its management and operation platform, actively promote endogenous growth and extensional development, and gradually implement the “Solid Solution Intelligent Factory Total Solution Supplier†and the strategic layout of the big health industry. In addition, the company continued to increase its investment in new markets and R&D investment in new products, further integrate internal and external resources, actively respond to customer needs, and strive to increase order turnover rates, thereby achieving steady growth in operating income. Qianshan Pharmaceutical Co., Ltd. analyzed the reasons from two aspects. The decrease in operating income was mainly due to the significant decrease in operating income of intelligent hybrid bale production automatic line, fully automatic combined fireworks production line and genetic testing chip products. The decrease in net profit attributable to shareholders of listed companies is due to the decrease in operating income of the first enterprise; the second is the provision for impairment of the goodwill of Hunan Lofudi Pharmaceutical Packaging Materials Co., Ltd., which is 31,387,200 yuan; Other receivables increased significantly year-on-year, and the corresponding impairment provision for other receivables increased significantly year-on-year. Fourth, financial expenses increased significantly year-on-year. Conclusion: The 2017 performance report of the five pharmaceutical equipment companies was mixed, and each family also analyzed the reasons for the increase in performance and the decline. What is certain is that at present, the market competition in the pharmaceutical equipment industry is fierce. Pharmaceutical equipment companies must not only actively upgrade and transform, respond to various challenges, but also increase research and development efforts to open up the equipment market. The development task is arduous and the pressure is also great. How to scientifically summarize the advantages and disadvantages of 2017, scientific planning 2018 development blueprint is what the pharmaceutical equipment enterprises should think about. Relevant experts suggest that the excellent performance of pharmaceutical equipment enterprises in 2017 should continue to be maintained, and the inadequacies should be actively changed and improved. 2018 is also a big medical policy year, industry development will accelerate, industry concentration will continue to improve, and pharmaceutical equipment companies will face opportunities and challenges. Can we balance the relationship between the two, stabilize the market position in the wave of competition, and achieve new breakthroughs by looking at the performance of the company itself. Wheat Seed,Winter Wheat Seed,Wheat Varieties,Organic Wheat Seeds XIKE AGRICULTURAL GROUP CO . .LTD. , https://www.laoseed.com
For the reason for the increase in performance, according to Chutian Technology's performance report, in 2017, Chutian Technology's new orders increased by more than 70% compared with 2016, and its main business income increased by 32% compared with the previous year. Affected by factors such as the launch of new products and increased price competition, the overall gross profit margin decreased, and the net profit increased slightly from the same period of the previous year.
5 pharmaceutical equipment companies 2017 performance report released